We expect Novo to gain $75 billion of a more than $200 billion global GLP-1 market in diabetes and obesity by 2031, ahead of semaglutide's 2032 patent expiration, with Lilly standing as the firm's key ...

SALT LAKE CITY - LifeVantage Corporation (NASDAQ:LFVN), a $271 million market cap player in the health and wellness sector with impressive 79% gross profit margins, today announced the successful ...

GLP-1 drugs like Ozempic and Wegovy revolutionized weight loss, but their high cost keeps them out of reach for most ...

Rapid fat loss from GLP-1 medications like Ozempic can lead to 'Ozempic face', characterized by hollow cheeks and sagging ...

The American Academy of Facial Plastic and Reconstructive Surgery (AAFPRS), the world's largest association of facial plastic and reconstructive surgeons, has released its highly anticipated 2024 ...

The Hain Celestial Group, Inc. ( NASDAQ: HAIN) Q2 2025 Earnings Conference Call February 10, 2025 8:00 AM ET Alexis Tessier - VP, IR Wendy Davidson - President & CEO Lee Boyce - CFO ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Healthcare stocks have something to offer every investor. If you're looking for high growth, you can try an innovative ...

The main difference between collagen and whey protein is their amino acid profile and health benefits. Collagen's amino acids ...

Q1 2025 Earnings Call Transcript February 4, 2025 Jacobs Engineering Group Inc. misses on earnings expectations. Reported EPS ...

Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...

At the request of BD, today's call is being recorded and will be available for replay on BD's Investor Relations website, investors.bd.com or by phone at 1-800-839-2486 for domestic calls and area ...